The expression of p53-target genes in the hypoxia-tolerant subterranean mole-rat is hypoxia-dependent and similar to expression patterns in solid tumors

Cell Cycle

Volumn 9, Issue 16, 2010, Pages 3367-3372

  Band, Mark ^a   Ashur Fabian, Osnat ^b   Avivi, Aaron ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b MEIR MEDICAL CENTER   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

Cancer; Hypoxia; p53 targeted genes; Subterranean mole rat

Indexed keywords

ANKYRIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ARGININE; CARBON DIOXIDE; CYTOGLOBIN; ERYTHROPOIETIN; HAPTOGLOBIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 3; LYSINE; MESSENGER RNA; NEUROGLOBIN; OXYGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BNIP3; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; VASCULOTROPIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA RESPONSIVE ELEMENT; GENE ACTIVATION; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; RAT; RNA EXTRACTION; SOLID TUMOR;

RATTUS; SPALAX;

EID: 77955744209     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.16.12712     Document Type: Article

References (59)

1. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004; 91:1415-9.
2. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
4. Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008; 7:2427-33.
5. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fahraeus R, Candeias MM. The p53 mRNA-Mdm2 interaction. Cell Cycle 2009; 8:31-4.
6. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88-91.
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
9. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFκB. Mol Pathol 1998; 51:55-61.
10. Nevo E. Mosaic Evolution of Subterranean Mammals: Regression, Progression and Global Convergence. Oxford University Press, Oxford 1999.
11. Nevo E, Ivanitskaya E, Beiles A. Adaptive Radiation of Blind Subterranean Mole Rats. Blackhuys, Leiden, 2001.
12. Avivi A, Resnick MB, Nevo E, Joel A, Levy AP. Adaptive hypoxic tolerance in the subterranean mole rat Spalax ehrenbergi: the role of vascular endothelial growth factor. FEBS Lett 1999; 452:133-40.
13. Widmer HR, Hoppeler H, Nevo E, Taylor CR, Weibel ER. Working underground: respiratory adaptations in the blind mole rat. Proc Natl Acad Sci USA 1997; 94:2062-7.
14. Shams I, Avivi A, Nevo E. Oxygen and carbon dioxide fluctuations in burrows of subterranean blind mole rats indicate tolerance to hypoxic-hypercapnic stresses. Comp Biochem Physiol A Mol Integr Physiol 2005; 142:376-82.
15. Avivi A, Shams I, Joel A, Lache O, Levy AP, Nevo E. Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat. FASEB J 2005; 19:1314-6.
16. Shams I, Nevo E, Avivi A. Ontogenetic expression of erythropoietin and hypoxia-inducible factor-1alpha genes in subterranean blind mole rats. FASEB J 2005; 19:307-9.
17. Shams I, Nevo E, Avivi A. Erythropoietin receptor spliced forms differentially expressed in blind subterranean mole rats. FASEB J 2005; 19:1749-51.
18. Band M, Joel A, Hernandez A, Avivi A. Hypoxia-induced BNIP3 expression and mitophagy: in vivo comparison of the rat and the hypoxia-tolerant mole rat, Spalax ehrenbergi. FASEB J 2009; 23:2327-35.
19. Band M, Joel A, Avivi A. The muscle ankyrin repeat proteins are hypoxia-sensitive: in vivo mRNA expression in the hypoxia-tolerant blind subterranean mole rat, Spalax ehrenbergi. J Mol Evol 2010; 70:1-12.
20. Peters KG, De Vries C, Williams LT. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci USA 1993; 90:8915-9.
21. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359:843-5.
22. Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha and carbonic anhydrase IX in human tumours. J Clin Pathol 2004; 57:504-12.
23. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 2006; 12:29-33.
24. Ashur-Fabian O, Avivi A, Trakhtenbrot L, Adamsky K, Cohen M, Kajakaro G, et al. Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation. Proc Natl Acad Sci USA 2004; 101:12236-41.
25. Veprintsev DB, Freund SM, Andreeva A, Rutledge SE, Tidow H, Canadillas JM, et al. Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci USA 2006; 103:2115-9.
26. Avivi A, Ashur-Fabian O, Joel A, Trakhtenbrot L, Adamsky K, Goldstein I, et al. p53 in blind subterranean mole rats - loss-of-function versus gain-of-function activities on newly cloned Spalax target genes. Oncogene 2007; 26:2507-12.
27. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 2001; 20:3449-55.
28. Moroni MC, Hickman ES, Lazzerini DE, Caprara G, Colli E, Cecconi F, et al. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3:552-8.
29. Wang B, Xiao Z, Ren EC. Redefining the p53 response element. Proc Natl Acad Sci USA 2009; 106:14373-8.
30. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14:6264-77.
31. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998; 392:405-8.
32. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
33. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12:461-8.
34. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1alpha and Mdm2 modulate p53 function. J Biol Chem 2003; 278:13595-8.
35. Nieminen AL, Qanungo S, Schneider EA, Jiang BH, Agani FH. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 2005; 204:364-9.
36. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by upregulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 2004; 64:4180-9.
37. Yuan JY, Horvitz HR. The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 1990; 138:33-41.
38. Cao G, Xiao M, Sun F, Xiao X, Pei W, Li J, et al. Cloning of a novel Apaf-1-interacting protein: a potent suppressor of apoptosis and ischemic neuronal cell death. J Neurosci 2004; 24:6189-201.
39. Cho DH, Hong YM, Lee HJ, Woo HN, Pyo JO, Mak TW, et al. Induced inhibition of ischemic/hypoxic injury by APIP, a novel Apaf-1-interacting protein. J Biol Chem 2004; 279:39942-50.
40. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001; 21:1297-310.
41. Magnusson KP, Satalino R, Qian W, Klein G, Wiman KG. Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation? Oncogene 1998; 17:2333-7.
42. Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage. Oncogene 2003; 22:3431-40.
43. Hernandez I, Maddison LA, Wei Y, DeMayo F, Petras T, Li B, et al. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and Mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res 2003; 1:1036-47.
44. Klein G. Cancer, apoptosis and nonimmune surveillance. Cell Death Differ 2004; 11:13-7.
45. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69:1237-45.
46. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-89.
47. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284:156-9.
48. Gagnebin J, Kovar H, Kajava AV, Estreicher A, Jug G, Monnier P, et al. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity. Oncogene 1998; 16:685-90.
49. Klein C, Planker E, Diercks T, Kessler H, Kunkele KP, Lang K, et al. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem 2001; 276:49020-7.
50. Ryan KM, Vousden KH. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 1998; 18:3692-8.
51. Ashur-Fabian O, Adamsky K, Trakhtenbrot L, Cohen Y, Raanani P, Hardan I, et al. Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis. Cell Cycle 2007; 6:589-94.
52. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El Naggar AK, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004; 36:63-8.
53. Menendez D, Inga A, Jordan JJ, Resnick MA. Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Oncogene 2007; 26:2191-201.
54. Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res 2009; 15:420-4.
55. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53:2231-4.
56. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J. Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem 2001; 276:6874-8.
57. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000; 20:209-15.
58. Pan Y, Haines DS. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells. Cancer Res 1999; 59:2064-7.
59. Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M, et al. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J Mol Biol 2000; 295:1009-21.